Physician profile
Malcolm T Stark
NPI 1891745261
$6,197.20
in general payments reported to CMS, 2019-2025
31 companies · $75.14 in 2025
The $75.14 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,171 · 2020: $127 · 2021: $736 · 2022: $650 · 2023: $714 · 2024: $724 · 2025: $75.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,513.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,130.69 | 2019-2024 | Xifaxan |
| Abbvie INC. | $863.42 | 2019-2024 | Skyrizi, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $238.09 | 2019-2024 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $225.39 | 2021 | |
| Janssen Biotech, INC. | $213.22 | 2020-2024 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $212.58 | 2021-2023 | Zeposia |
| Pfizer INC. | $181.42 | 2019-2024 | |
| Pentax of America, INC. | $165.49 | 2020-2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Boston Scientific Corporation | $127.15 | 2019-2023 | Exalt Model D |
| Medtronic, INC. | $102.55 | 2024 | Gi Genius |
| Genzyme Corporation | $100.64 | 2023-2024 | |
| Endogastric Solutions, INC | $83.26 | 2023 | Esophyx |
| Intercept Pharmaceuticals, INC. | $50.90 | 2022-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $49.72 | 2021-2023 | Rebyota |
| Redhill Biopharma INC. | $48.03 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $40.57 | 2021-2022 | |
| Ucb, INC. | $40.39 | 2019 | |
| Phathom Pharmaceuticals, INC. | $39.73 | 2023-2024 | Voquezna |
| Aimmune Therapeutics, INC. | $34.57 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $30.30 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $28.04 | 2021 | |
| Braintree Laboratories, INC. | $27.72 | 2019-2020 | |
| Ardelyx, INC. | $26.68 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $25.17 | 2019-2021 | |
| Medtronic USA, INC. | $22.83 | 2020 | |
| Olympus America INC. | $17.80 | 2023 | Endoclot Phs |
| Cook Medical LLC | $16.54 | 2025 | Echotip Insight |
| Evoke Pharma, INC. | $16.25 | 2021 | |
| Fresenius Kabi USA, LLC | $13.42 | 2024 | Idacio |
| Shire North American Group INC | $13.32 | 2019 | |
| Allergan, INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.